Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
With EU knockback laquinimod's irrelevance is all but assured | Evaluate
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod | C19H17ClN2O3 - PubChem
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Teva & Active Biotech Press Release: November 4, 2014
Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
Active Biotech regains rights of laquinimod from Teva
Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Laquinimod - Wikipedia
First patient enrolled in Phase II study evaluating laquinimod
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
